1. Home
  2. NOM vs SABS Comparison

NOM vs SABS Comparison

Compare NOM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Missouri Quality Municipal Income Fund

NOM

Nuveen Missouri Quality Municipal Income Fund

HOLD

Current Price

$11.21

Market Cap

26.3M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.95

Market Cap

187.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOM
SABS
Founded
1993
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
187.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NOM
SABS
Price
$11.21
$3.95
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.80
AVG Volume (30 Days)
6.9K
354.4K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
3.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.52
$1.00
52 Week High
$10.48
$6.60

Technical Indicators

Market Signals
Indicator
NOM
SABS
Relative Strength Index (RSI) 48.86 54.00
Support Level $11.05 $3.80
Resistance Level $12.00 $4.14
Average True Range (ATR) 0.30 0.25
MACD -0.07 0.01
Stochastic Oscillator 33.61 62.82

Price Performance

Historical Comparison
NOM
SABS

About NOM Nuveen Missouri Quality Municipal Income Fund

Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: